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An efﬁcient and novel total synthesis of the two bioactive retinoids temarotene and arotinoid acid
(TTNPB) is described. The key steps in this process include the regio and stereoselective hydrotelluration
of thioacetylene 9 and Te/Li transmetalation of mixed (Z)-1,2-bis(organylchalcogene)-1-alkene (Z)-3. The
subsequent reaction involving the b-phenylthio vinyl lithiated intermediate 10 with dimethyl sulfate
gave the (E)-vinyl sulﬁde 11. The Ni+2 cross-coupling of 11 with the corresponding phenylzinc bromide
and p-oxazoline phenylzinc bromide 12 afforded the respective temarotene 2 and retinoid-oxazoline
substituted 13. Finally, compound 13 was deprotected with HCl to furnish arotinoid acid (TTNPB) 1.
 2012 Elsevier Ltd. All rights reserved.O
OH
21Naturally occurring vitamin A-like compounds such as all-trans-
retinoic acid (atRA)1,2 are responsible for regulating growth and
differentiation in the cell, and many of them have shown promis-
ing anticancer effects.3–7 However, monocutaneous irritation,
hyperlipidemia, bone toxicity, impaired night vision, and teratoge-
nicity, have been observed as side effects after the use of these sub-
stances in therapy.8 The analogues of atRA include the arotinoid
acid 4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-napht-
halenyl)-1-propen-1-yl] benzoic acid 1 (TTNPB)9 which is a potent
synthetic retinoid that shows a similar afﬁnity as atRA, binding to
all three nuclear retinoic-acid receptors (RARs).10
Bioassays in vivo and in culture showed that TTNPB is more
potent than atRA, mainly because of its higher molecular stabil-
ity.11 The effects of TTNPB, which include control of epidermal
keratinocytes12 and murine teratocarcinoma cells13 and antiprolif-
erative effects on Kaposi´s sarcoma,14 breast cancer,15 cervical car-
cinoma,16 and leukemia cells17 have been known for some time.
Furthermore, TTNPB proved to be 100 times more effective than
atRA in inhibiting the growth of breast cancer cells.18 However,
TTNPB is more teratogenic than atRA, which limits its use as a che-
motherapeutic agent in humans.19 Thus, synthetic methodologiesll rights reserved.
.).to prepare less toxic retinoid derivatives than TTNPB have been
described. In this way, the [(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tet-
rahydro-2-naphthalenyl)]-1-phenyl-1-propene, known as temaro
tene20 2, has long been used for chemoprevention of cancer21
and has shown no important side effects such as hypervitaminosis
A and teratogenicity. The lack of side effects is believed to be a con-
sequence of the absence of the polar carboxyl group22 as shown in
Figure 1.
Srebnik and co-workers described the stereospeciﬁc synthesis
of temarotene using the metal catalyzed cross-coupling reactionsArotinoid acid
TTNPB Temarotene
Figure 1. Chemical structure of retinoid products.
OH
OH
HCl (conc)/r.t.
Cl
Cl
AlCl3/CH2Cl2//reflux
Br
Br
OH
H
OH
1) NaH/toluene
reflux
1) n-C4H9Li/THF -78 oC
2) C6H5SSC6H5/r.t.
H
SC6H5
1) C4H9TeLi/H2O
THF/reflux
2) HCl (0.1M)/ r.t.
SC6H5C4H9Te
(Z)-3
45 6
7 8
9
90 %
PdCl2/CuI/MeOH/Et3N/r.t.
)))
80 %
75 %
70 %
95 % 80 %
2) H2O/r.t.
Scheme 1. Synthesis of fragment 3.
SC6H5C4H9Te
n-C4H9Li
THF/-78oC
SC6H5Li
(CH3)2SO4/THF/-78 oC
SC6H5
(Z)-3 10
(E)-11
85 %
Scheme 2. Synthesis of fragment 11.
P. G. Guerrero Jr. et al. / Tetrahedron Letters 53 (2012) 5302–5305 5303of gem-borazirconocene-1-alkenes.23 However, the 1,1-dihetero
bismetallic intermediate was generated by the hydrozirconation
of 1-alkynylboranate with the expensive and air-sensitive
Cp2Zr(H)Cl (Schwart´s reagent).
More recently, Dame and co-workers described the 4-hydroxy-
benzyl structural modiﬁcations in TTNPB with N-(4-hydroxy-
phenyl) amido (4HPTTNPB) and 4-hydroxybenzyl (4-HBTTNB),
investigated their high potential to induce apoptosis in breast can-
cer cells and demonstrated their low toxicity.24
Normally, TTNPB and analogues used in bioassay studies are
synthesized upon Horner-Emmons oleﬁnation of aryl ketones
using the anion diethyl(4-carboethoxybenzyl) phosphonate.25
However, this method can lead to a diasteroisomeric mixture25,26
of (Z) and (E)-TTNPB-type, and the use of phosphorus reagents
has been avoided recently due to their high toxicity and generation
of hazardous residues, and the tedious procedures involved in
product puriﬁcation, which limits the use of this protocol.27
Considering the interesting biological activities of the retinoids
TTNPB and temarotene, and the need to apply these molecules as aprototype to construct new anticancer drugs, we describe herein a
novel and straightforward total synthesis of these two (E)-reti-
noids with total regio and stereochemical control, by modiﬁcations
of procedures described in the literature.25 The key intermediate
for both syntheses is (Z)-1-phenylthio-2-butyltelluro-2-[5,5,8,8-
tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl] ethene 3 which
was prepared as outlined in Scheme 1.
Thus, the solid 2,5-dichloro-2,5-dimethyl-hexane 4 was ob-
tained in 90% yield by the addition of concentrated HCl to a
solution containing 2,5-dimethyl-2,5-hexanediol 5.25b Friedel-
Crafts alkylation28 of bromobenzene in the presence of AlCl3 with
dichloride compound 4 led to the bromo substituted tetralin 6.
Applying a Sonogashira-type cross-coupling reaction protocol re-
cently developed by us29 between 6 and 1,1-dimethyl-3-propyn-
1-ol employing a system containing PdCl2/CuI/Et3N in methanol
under sonication, afforded the disubstituted bicyclic alkyne 7
(75% yield). The retro-Favorskii conditions30 were utilized by
deprotection of the terminal triple bond of 7 using NaH/toluene
under reﬂux to give the terminal bicyclic alkyne 8 in 70% yield,
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acetylene 9 in 95% yield by the reaction with n-C4H9Li/THF
followed by the addition of phenyl disulﬁde. Finally, performing
the hydrotelluration31,32 of 9 with C4H9TeLi/H2O the (Z)-1-phenyl-
thio-2-butyltelluro-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-
naphthalenyl) ethene 3 was achieved in 80% yield.
The next step in the synthesis of the desired compounds in-
volved the selective Te/Li transmetalation of the key compound 3
with n-C4H9Li to produce the lithiated b-organylthio vinyl as
recently described by our group.31 As far as we know this is the
ﬁrst time that this transformation has been applied in the total
synthesis of bioactive molecules.
Therefore, the reaction of (Z)-1-phenylthio-2-butyltelluro-2-
(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl) ethene 3
with n-C4H9Li at 78 C produced in situ the b-phenylthio vinyl
lithiated intermediate 10, which was reacted with dimethyl sulfate
to give the trisubstituted vinyl sulﬁde 11 in 85% yield (Scheme 2).32
So, the Ni+2 cross-coupling reaction of alkenyl sulﬁde 11 with
the commercially available phenylzinc bromide or 2-(4-bromophe-
nyl zinc)-4,4-dimethyl-2-oxazoline 12 [prepared separately by the
addition of dry ZnBr2 (1.0 equiv) at 0 C to a solution of the
2-(4-bromophenylmagnesium)-4,4-dimethyl oxazoline33 (1.0 equiv)
in THF] using the inexpensive catalyst Ni(dppe)Cl2, furnished
respectively, the temarotene 2 in 62% yield and the oxazolineintermediate 13, in 63% yield. Finally, the compound 13 was
converted into arotinoid acid (TTNPB) in 85% yield by the hydroly-
sis of the oxazoline moiety using HCl (3 N) under reﬂux (Scheme
3).
In conclusion, we describe herein a novel and efﬁcient total syn-
thesis of the two important bioactive retinoids, temarotene, and
arotinoid acid (TTNPB), using a selective stereocontrolled Te/Li trans-
metalation of the mixed (Z)-1,2-(organylchalcogenide)-1-alkene
followed by Ni+2 catalyzed cross-coupling reaction between a vinyl
sulﬁde with organozinc reagent as the key steps. Moreover, we
describe for the ﬁrst time the synthetic application of the b-organyl-
thio vinyl lithiated intermediates type 10, toward the total synthesis
of bioactive molecules.
Further studies concerning the use of mixed (Z)-1,2-(organyl-
chalcogenide)-1-alkenes to make interesting bioactive molecules
such as sex pheromones and other anticancer synthetic retinoids
such as bexarotene are in progress in our laboratory.
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(E)-1-Phenylthio-2-[5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2 naphthalenyl]-1-
propene (11): To a two-neck ﬂask under nitrogen atmosphere and magnetic
stirring bar containing a solution of (Z)-1-phenylthio-2-butyltelluro-2-[5,5,8,8-
tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl]-ethene (3) (0.75 g, 1.5 mmol)
in THF (5.0 mL) at 78 C, n-butyllithium (1.5 mL, 1.5 mmol, 1.0 M in hexanes)
was transferred via syringe and the reaction was stirred for 10 min. Next,
dimethyl sulfate (0.20 mL, 2.0 mmol) was added and themixturewas stirred for
additional 30 min. The reaction mixture was left to reach 25 C, diluted with
ethyl acetate (100 mL), and washed with brine (4  50 mL). The organic phase
was dried under anhydrous MgSO4. After ﬁltration, the solvent was removed
under vacuum and the crude product puriﬁed by ﬂash chromatography in silica
gel (230–400 mesh) using hexane as mobile phase to give the pure compound
(E)-11 as yellowoil in 85% yield (0.28 g). IR (neat): 2925, 1850, 1755, 1494, 1458,
920, 689 cm1 1H NMR (400 MHz, d in CDCl3) 7.12–7.41 (m, 8H), 6.55 (s, 1H),
2.25 (s, 3H), 1.67 (s, 4H), 1.27 (s, 6H), 1.24 (s, 6H); 13C NMR (75 MHz) 144.2,
144.1, 138.8, 138.4, 136.5, 128.9, 128.7, 126.5, 126.1, 123.4, 122.8, 119.6, 35.1,
34.9, 34.2, 34.0, 31.8, 31.5; GC/MSm/z required for C23H28S (M+) 336.5, observed
336.3.
4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8 tetrahydro-2-naphthalenyl)]-1-phenyl-1-
propene (2) (Temarotene): To a two-neck ﬂask under nitrogen atmosphere and
magnetic stirring bar containing a solution of (E)-1-Phenylthio-2-[5,5,8,8-
tetramethyl-5,6,7,8-tetrahydro-2 naphthalenyl]-1-propene (11) (0.34 g,
1.0 mmol) in THF (8 mL) and NiCl2(dppe) (0.026 g, 0.05 mmol) was added
dropwise via syringe the C6H5ZnBr (4 mL, 2 mmol, 0.5 M in THF) and the
mixturewas stirred for 2.5 h under reﬂux. The reactionmixturewas left to reach
25 C, diluted with ethyl acetate (100 mL) and washed with brine (5  50 mL).
The organic phase was dried under anhydrous MgSO4. After ﬁltration, the
solvent was removed under vacuum and the crude product puriﬁed by ﬂash
chromatography in silica gel (230–400 mesh) using hexane as mobile phase to
give the pure temarotene 2 as yellow oil in 55% yield (0.16 g). IR (neat) 2925,
1607, 1458, 922 cm1; 1H NMR (400 MHz, d in CDCl3) 7.43 (d, J = 7.5 Hz, 1H),
7.33–7.35 (m, 4H), 7.29 (d, J = 7.5 Hz, 2H), 7.24 (m, 1H), 6.78 (s, 1H), 2.25 (s, 3H),
1.69 (s, 4H), 1.31 (s, 6H), 1.27 (s, 6H); 13C NMR (75 MHz) 144.8, 144.1, 141.0,
138.6, 137.6, 129.1, 128.1, 127.0, 126.7, 126.4, 124.1, 123.5, 35.2, 34.1, 40.1, 31.9,
17.4; HRMS (70 eV) required for C23H28 (M+) 304.2191, observed 304.2182.
2-[4-(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-
1yl]phenyl-4,4-dimethyl-2-oxazoline (13): To a two-neck ﬂask under nitrogen
atmosphere andmagnetic stirring bar containing a solution of (E)-1-phenylthio-
2-[5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl]-1-propene 11
(0.34 g, 1.0 mmol) in THF (8.0 mL) and Ni(dppe)Cl2 (0.026 g, 0.05 mmol) was
added dropwise via syringe the 2-(4-bromophenyl zinc)-4,4-dimethyl-2-
oxazoline 12 (2.0 mmol) [prepared separately by addition of dry ZnBr2 (0.45 g,
2.0 mmol) to a solution of 2-(4-bromophenyl magnesium)-4,4-dimethyl
oxazoline33 (2.0 mmol) in THF (4.0 mL) at 0 C and the mixture was stirred for
30 min] and the reaction stirred for 5 h under reﬂux. After cooling the mixture
was dilutedwith ethyl acetate (100 mL) andwashedwith brine (5  50 mL). The
organic phase was dried under anhydrous MgSO4. After ﬁltration, the solvent
was removed under vacuum and the crude product puriﬁed by ﬂash
chromatography in silica gel (230–400 mesh) and hexane/ethyl acetate (9:1 v/
v) as mobile phase to give the pure compound (E)-13 in 63% (0.25 g). IR (neat)
2923, 1847, 1635, 1610, 1417, 920 cm1; 1H NMR (400 MHz, d in CDCl3) 7.95 (d,
J = 7.5 Hz, 2H), 7.52 (d, J = 7.5 Hz, 2H), 7.50 (s, 1H), 7.16 (s, 1H), 7.10 (s, 1H), 6.75
(s, 1H), 4.10 (s, 1H), 1.95 (s, 3H), 1.71 (s, 4H), 1.38 (s, 6H), 1.30 (s, 6H), 1.25 (s,
6H); 13C NMR (75 MHz) 162.0, 149.2, 144.2, 143.2, 138.1, 132.7, 128.0, 126.8,
116.2, 79.0, 67.5, 35.1, 33.9, 31.9, 28.4, 19.9; Anal. Calcd for C28H35NO: C, 76.19;
H, 8.73, Found C, 76.34; H, 8.90.
4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-
1yl]benzoic acid (1) (TTNPB): A solution containing (E)-13, (2.0 g, 5.0 mol) and
hydrochloric acid (65 mL, 3 N) was reﬂuxed for 3 h. Next, the reaction was
cooled to 0 C when a white precipitate formed. After ﬁltration, the white
crystals were washed with water (2  30 mL) and the solid crude product was
recrystallized from acetic acid, furnishing the pure TTNPB 1 in 85% yield (0.31 g).
mp 240–24 C (lit. mp 239–240 C)24; UV (DMSO) kmax 312 nm (lit. kmax
309 nm);24 IR (Nujol) 1680, 1604, 1567, 795 cm1; 1H NMR (400 MHz, d in
CDCl3) 7.95 (d, J = 7.5 Hz, 2H), 7.52 (d, J = 7.5 Hz, 2H), 7.50 (s, 1H), 7.31 (s, 2H),
6.89 (s, 1H), 2.25 (s, 3H), 1.65 (s, 4H), 1.28 (s, 6H), 1.24 (s, 6H); 13C NMR (75 MHz)
167.7, 144.8, 144.5, 142.9, 140.7, 139.6, 129.7, 129.6, 129.2, 126.9, 126.1, 124.2,
123.9, 35.2, 35.0, 34.5, 34.3, 32.1, 32.0, 17.9; Anal. Calcd for C24H28O2: C, 82.74;
H, 8.45, Found C, 83.02; H, 8.78.
33. The magnesium reagent 2-(4-bromophenyl magnesium)-4,4-dimethyl
xazoline was generated in situ as described by Meyers, A. I.; Temple, D. L.;
Haidukewych, D.; Mihelich, E. D. J. Org. Chem. 1974, 39, 2787.
